Business context and reporting period
This is Ziopharm Oncology, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2016. The filing identifies the registrant as Ziopharm Oncology, Inc.; the request metadata names Alaunos Therapeutics, Inc., so the company identity should be verified. Ziopharm was a development-stage biopharmaceutical company focused on immuno-oncology and graft-versus-host disease (GvHD), with no approved products and minimal collaboration revenue.
Financial performance and liquidity
Amounts below are U.S. dollars; financial statement figures were reported in thousands.
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Collaboration revenue | 2016: $1.697 million; 2015: $0.272 million | 2016: $3.666 million; 2015: $0.544 million |
| Research and development expense | 2016: $129.228 million; 2015: $7.424 million | 2016: $139.427 million; 2015: $81.673 million |
| General and administrative expense | 2016: $3.711 million; 2015: $7.073 million | 2016: $7.521 million; 2015: $11.323 million |
| Net loss | 2016: $131.200 million; 2015: $14.211 million | 2016: $143.219 million; 2015: $92.442 million |
| Net loss per share, basic and diluted | 2016: $1.01; 2015: $0.11 | 2016: $1.10; 2015: $0.76 |
- At June 30, 2016, cash and cash equivalents were $109.0 million, down from $140.7 million at December 31, 2015. Cash equivalents included $106.1 million in a Treasury money market fund.
- Six-month operating cash use was $31.2 million, versus $21.4 million in 2015; investing cash use was $0.3 million. Financing cash use was $0.3 million, compared with $97.2 million provided in 2015, primarily from that year’s public offering.
- Working capital was $110.7 million, versus $134.4 million at year-end 2015. Total liabilities were $180.0 million and stockholders’ deficit was $52.0 million. The balance sheet lists no conventional borrowing debt; liabilities included a $119.0 million Series 1 preferred stock issuance obligation and $51.1 million of deferred revenue.
- The filing does not provide a meaningful product gross margin; the company had no approved products and revenue consisted primarily of collaboration revenue.
Material changes and unusual items
- Second-quarter R&D expense included a $119.1 million noncash charge for the fair value of Series 1 preferred shares promised to Intrexon under amendments to the cancer and GvHD collaborations. The charge drove the unusually large quarterly loss. The shares were issued July 1, 2016.
- The June 2016 amendments reduced Intrexon’s share of net profits from 50% to 20% under the cancer and GvHD agreements. The reduction does not apply to specified sublicensing revenue and royalties. In exchange, Ziopharm agreed to issue 100,000 Series 1 preferred shares, each with a $1,200 stated value.
- The preferred shares carry a 1% monthly dividend payable in additional preferred shares, with a higher rate on shares remaining unconverted after a specified conversion event. Conversion is tied to the first U.S. product approval under specified agreements and is subject to Nasdaq-related limits absent shareholder approval. The filing describes liquidation participation and protective rights for preferred holders.
- Revenue growth reflected recognition of Ares Trading collaboration upfront proceeds over an estimated nine-year service period. Deferred revenue from that agreement was $51.1 million at June 30, 2016; it is not equivalent to cash newly received in the period.
- Six-month R&D expense also reflected ongoing cell-therapy and immuno-oncology development. The prior-year comparison included a $67.3 million noncash charge for shares issued for the MD Anderson license.
Outlook, clinical developments, and risks
- Management estimated existing cash would fund operations into the fourth quarter of 2017, based on current development plans. It also stated that additional financing would be needed for longer-term trials and product development, with no committed source of additional capital. Actual cash needs could differ materially; financing may be dilutive or unavailable on acceptable terms.
- Clinical programs included Ad-RTS-IL-12 plus veledimex in recurrent or progressive glioma and breast cancer, and CAR T, NK-cell, TCR, and GvHD research. The glioma Phase 1 study had opened a third dosing cohort; management planned further updates and a combination study with an immune checkpoint inhibitor in 2016. A pediatric glioma study was planned for 2017.
- In a company-reported interim glioma dataset of 11 patients presented at ASCO, 10 were alive at the May 18, 2016 data cutoff, with median follow-up of 6.2 months. These were small, early-stage data and not proof of efficacy. The filing also reports serious adverse events and a third reported patient death later determined by the trial safety committee to be unrelated to study drug; the trial remained open to enrollment.
- Other stated 2016 objectives included advancing a CD33 CAR T trial, an investigator-led off-the-shelf NK-cell study, and preclinical work in TCR and GvHD programs. These were plans, not assured outcomes.
- Key risks include clinical failure or delay, treatment-related toxicity, regulatory uncertainty for gene and cell therapies, manufacturing and supply constraints, reliance on Intrexon and MD Anderson licenses and collaborators, competition, intellectual-property disputes, and the need for additional capital. Management reported disclosure controls were effective and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the issuer and security being analyzed: this filing is for Ziopharm Oncology, Inc., not a registrant named Alaunos Therapeutics, Inc.
- Review the Series 1 preferred stock terms and subsequent issuance, including accruing dividends, conversion mechanics, liquidation rights, and potential common-stock dilution.
- Assess the $119.0 million noncash preferred-stock charge separately from recurring operating costs and confirm its accounting and subsequent balance-sheet classification.
- Track cash burn, the assumptions behind the stated fourth-quarter 2017 runway, and the timing and terms of any future financing.
- Evaluate clinical evidence using full trial data, patient follow-up, safety reporting, and regulatory updates rather than interim company-reported results alone.